IP Library Granted Patent US 10,350,287
Granted Patent B2
US 10,350,287 · App. 15/233,013 · Granted Jul 16, 2019

Hendra virus recombinant compositions and uses thereof

Inventors: Jean-Christophe Audonnet (Lyons, FR); Jules Maarten Minke (Corbas, FR); Teshome Mebatsion (Watkinsville, GA); Catherine Charreyre (Lyons, FR)
Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
A61K39/155A61K39/12C07K14/005C12N7/00A61K2039/505A61K2039/5254A61K2039/5256A61K2039/53A61K2039/545A61K2039/70C12N2710/24043C12N2760/18222C12N2760/18234C12N2799/023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,350,287
App. No.
15/233,013
Granted
Jul 16, 2019
Kind
B2
Abstract

The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.

Claims (12)

1. A method of vaccinating an animal to provide direct protection against Hendra virus and cross-protection against Nipah virus, comprising:

administering to the animal a vaccine composition comprising (i) a first ALVAC vector encoding a Hendra virus G polypeptide having SEQ ID NO:3 and a second ALVAC vector encoding a Hendra virus F polypeptide having SEQ ID NO:6; or (ii) a single ALVAC vector encoding the Hendra virus G polypeptide and the Hendra virus F polypeptide, wherein the vaccine composition is administered to the animal at a dose of at least 5.5 log 10 TCID 50 .

2. The method of claim 1 , wherein the vaccine composition further comprises an additional antigen.

3. The method of claim 2 , wherein the additional antigen is a Nipah antigen.

4. The method of claim 1 , wherein the Hendra virus G polypeptide is encoded by a polynucleotide having SEQ ID NO:1 or 2, and wherein the Hendra virus F polypeptide is encoded by a polynucleotide having SEQ ID NO: 4 or 5.

5. The method of claim 1 , wherein the vaccine composition further comprises a pharmaceutically or veterinarily acceptable vehicle, adjuvant, diluent, or excipient.

6. The method of claim 1 , wherein the method comprises a prime-boost administration protocol.

7. The method of claim 1 , wherein the animal is a horse.

8. The method of claim 7 , wherein the vaccine composition is administered to the horse at a dose of at least 5.5 log 10 TCID 50 .

9. The method of claim 1 , wherein the vaccine composition comprises the first ALVAC vector and the second ALVAC vector.

10. The method of claim 1 , wherein the vaccine composition comprises the single ALVAC vector.

11. The method of claim 1 , wherein the vaccine composition is administered by intramuscular route.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2019
From: MERIAL, INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 049218/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2016
From: MERIAL LIMITED
To: MERIAL, INC.
Reel/Frame 039665/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2016
From: AUDONNET, JEAN-CHRISTOPHE; MEBATSION, TESHOME; MINKE, JULES MAARTEN; CHARREYRE, CATHERINE
To: MERIAL LIMITED
Reel/Frame 039397/0361 →
Continuity (3)
Division 13478165 · May 23, 2012
Provisional Application 61491037 · May 27, 2011
Related Publication 20170087242A1 · Mar 30, 2017
Cited By (1)
US 12,247,071